Jazz Pharmaceuticals plc — Director's Dealing 2012

Mar 13, 2012

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Jazz Pharmaceuticals plc (JAZZ)
CIK: 0001232524
Period of Report: 2012-03-09

Reporting Person: Mulligan Seamus (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2012-03-09	Ordinary Shares, nominal value $0.0001 per share	S	2000000	$49.56	Disposed	3291009	Direct
2012-03-09	Ordinary Shares, nominal value $0.0001 per share	G	864954	—	Disposed	2426055	Direct
2012-03-09	Ordinary Shares, nominal value $0.0001 per share	G	864954	—	Acquired	864954	Indirect

Footnotes

F1: On March 9, 2012, the Reporting Person completed the sale of 2,000,000 ordinary shares to Barclays Capital Inc. and Citigroup Global Markets Inc., as underwriters in connection with a public offering of a total of 7,883,366 ordinary shares by certain shareholders of the Issuer, including the Reporting Person.

F2: On March 9, 2012, the Reporting Person transferred for no consideration a total of 864,954 ordinary shares to The Barrymore Trust, consisting of 432,477 ordinary shares that the Reporting Person held directly and 432,477 ordinary shares that the Reporting Person held in his name on behalf of his wife, Deirdre Mallon. The Barrymore Trust is a discretionary family trust the beneficiaries of which are the Reporting Person, his wife and his children.

F3: Following the consummation of the transactions described in footnotes (1) and (2), above and (4) below, the Reporting Person will beneficially own a total of 3,291,009 ordinary shares of the Issuer, consisting of 2,426,055 ordinary shares held directly by the Reporting Person and 864,954 ordinary shares held by The Barrymore Trust. See Exhibit A to this report for a discussion of the escrow arrangements to which 569,160 ordinary shares of the Reporting Person are subject.

F4: The Reporting Person voluntarily reported on his Form 3 filed on January 18, 2012 that he held 400,590 ordinary shares in his name, as nominee, in trust for nineteen other individuals. Under the trust deed pursuant to which the Reporting Person held the ordinary shares, the Reporting Person had sole voting power, but no dispositive power or pecuniary interest in such shares and, accordingly, disclaimed beneficial ownership of such shares in the Form 3. On March 9, 2012, the Reporting Person resigned from his position as nominee/trustee under the trust deed and transferred for no consideration all of the 400,590 ordinary shares to a third party who agreed to act as nominee/trustee under the trust deed. Accordingly, the Reporting Person no longer has any voting power with respect to such shares. Since the Reporting Person did not have any pecuniary interest in such ordinary shares, the transfer is not reflected in Table I above in accordance with SEC rules.